Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer’s disease in an animal model.
Their findings are published in the Aug. 5 issue of the journal PLoS Biology.
The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer’s.
“Decreasing STEP levels reversed the effects of Alzheimer’s disease in mice,” said lead author Paul Lombroso, M.D., professor in the Yale Child Study Center and in the Departments of Neurobiology and Psychiatry at Yale School of Medicine.
Lombroso and co-authors studied thousands of small molecules, searching for those that would inhibit STEP activity. Once identified, those STEP-inhibiting compounds were tested in brain cells to examine how effectively they could halt the effects of STEP. They examined the most promising compound in a mouse model of Alzheimer’s disease, and found a reversal of deficits in several cognitive exercises that gauged the animals’ ability to remember previously seen objects.
Read more . . .
The Latest on: Alzheimer’s drug
[google_news title=”” keyword=”Alzheimer’s drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Alzheimer’s drug
- For Beaten-Down Maker of Alzheimer’s Drug, Good Enough Will Doon April 25, 2024 at 8:00 am
In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.
- Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Whyon April 24, 2024 at 11:23 am
Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA ...
- Biogen cost cuts drive profit beat, as Alzheimer's drug off to slow starton April 24, 2024 at 9:15 am
Biogen reported a quarterly profit that topped Wall Street estimates, helped by cost cutting, as the launch of its new Alzheimer's disease drug remained sluggish. Sales of Alzheimer's drug Leqembi, ...
- Biogen’s Alzheimer’s drug launch on ‘steady pace’ as logistical hurdles recedeon April 24, 2024 at 8:06 am
Biogen on Wednesday reported first-quarter earnings that beat Wall Street expectations largely on reduced expenses.
- Biogen Beats Estimates as Alzheimer’s Drug Gains Tractionon April 24, 2024 at 6:34 am
Biogen Inc. reported first-quarter profit that beat Wall Street’s expectations as the biotech giant’s new Alzheimer’s drug Leqembi gained traction and cost cuts took hold.Adjusted earnings for the ...
- Alzheimer’s Drug Leqembi Finally Sees Sales Pickupon April 24, 2024 at 5:39 am
Sales of a groundbreaking new Alzheimer’s disease treatment from Eisai and Biogen are finally accelerating, after a sluggish launch last year. Biogen said Wednesday that the number of patie ...
- Biogen beats quarterly profit estimates, Alzheimer's drug sales jumpon April 24, 2024 at 3:48 am
Biogen beat Wall Street estimates for first-quarter profit on Wednesday, helped by a series of cost-cutting measures as older drugs face fierce competition.
- Biogen stock climbs on strong Alzheimer’s drug saleson April 23, 2024 at 5:00 pm
Biogen on Wednesday reported a first-quarter profit that exceeded estimates as the Cambridge drug maker cut costs and sales of its closely watched Alzheimer’s drug, Leqembi, surpassed expectations.
- Alzheimer's drug development pipeline: Positive results, new insight on biomarkers position 2024 as 'learning year'on April 23, 2024 at 5:00 pm
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials. On the heels of newly FDA-approved drugs Aduhelm (aducanumab ...
- Alzheimer's drug adoption in US slowed by doctors' skepticismon April 23, 2024 at 10:26 am
Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among ...
via Bing News
